
    
      Lacosamide is administered for patients with amyotrophic lateral sclerosis (ALS). This
      clinical trial is open-label, single group and before and after comparison study. Dosage of
      lacosamide is increased from 100mg to 400mg for 4 weeks. Safety of lacosamide administration
      in ALS is primary endpoint. Nerve excitability, fasciculation and muscle cramp are
      investigated before and after administration for secondary endpoints.
    
  